Dulaglutide

What it is

Dulaglutide is an injected protein medicine: a modified copy of the human gut hormone GLP-1 fused to part of an antibody so it survives in the blood for about a week. It shares 90% of its amino acid sequence with natural human GLP-1. It is given as a once-weekly subcutaneous injection and is not absorbed if swallowed.

What the research says

In the REWIND trial (9,901 people, median 5.4 years) it reduced the combined rate of heart attack, stroke and cardiovascular death from 13.4% to 12.0%, a hazard ratio of 0.88, while all-cause mortality did not differ. In AWARD-11 it lowered HbA1c by about 1.5 to 1.9 percentage points and body weight by 3 to 4.7 kg over 36 weeks, dose-dependently. The trade-off is gastrointestinal: nearly half of REWIND participants on dulaglutide reported a gastrointestinal adverse event, against about a third on placebo. It carries a boxed warning about thyroid C-cell tumours seen in rats, and the human observational evidence on thyroid cancer is contradictory.

Evidence grade: Well established.

How it works

Drug class: Glucagon-like peptide-1 (GLP-1) receptor agonist

It switches on the GLP-1 receptor on insulin-producing cells in the pancreas, which makes them release insulin when blood glucose is high but not when it is normal. It also turns down glucagon, the hormone that raises blood sugar, and slows the stomach emptying, which blunts the post-meal glucose rise and reduces appetite. (Source 1)

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)]. TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY [see Contraindications (4) and Warnings and Precautions (5.1)].

(Source 2)

What it is used for

• In AWARD-11 (1,842 patients on metformin), 36 weeks of dulaglutide lowered HbA1c by 1.54% at 1.5 mg and 1.77% at 4.5 mg on the treatment-regimen estimand, with 4.5 mg superior to 1.5 mg (P<0.001). The 3.0 mg dose was superior on the efficacy estimand but not on the treatment-regimen estimand (P=0.096). The trial was industry-sponsored. Evidence: established. (Source 3)
• REWIND randomised 9,901 people to dulaglutide 1.5 mg weekly or placebo for a median 5.4 years. The primary composite outcome fell from 663/4,952 (13.4%) to 594/4,949 (12.0%), HR 0.88 (95% CI 0.79-0.99, p=0.026) - an absolute difference of about 1.4 percentage points over more than five years. All-cause mortality was not significantly reduced. Funded by Eli Lilly and Company. Evidence: established. (Source 4)
• Dulaglutide is not approved for weight management; the label's indications cover glycaemic control and cardiovascular risk only. Weight loss in its diabetes trials was modest and dose-dependent (4.7 kg versus 3.1 kg at 36 weeks in AWARD-11), and class-wide evidence shows most of the weight returns after stopping. Evidence: limited. (Source 5)

Interactions

• Oral medicines and oral supplements taken at the same time (label): Because dulaglutide slows the stomach emptying, anything swallowed may be absorbed more slowly. The effect is largest after the first dose and fades with later ones. The label frames this for oral medicines; the same mechanism applies to oral supplements, which is an inference rather than a measured finding. (Source 6)
• Sulfonylureas and insulin (label): Dulaglutide alone rarely causes low blood sugar, but combined with these it can. The label's advice to consider lowering the secretagogue or insulin dose is written for the point at which dulaglutide is started, not as open-ended guidance, and it is a regulatory position dated 2026 rather than a trial result. (Source 7)

Stopping it

• There is no withdrawal syndrome, but the metabolic effect is not durable. A systematic review and nonlinear meta-regression of GLP-1 receptor agonist cessation found about 60% of lost weight returned within a year, with the trajectory extrapolated to plateau at about three-quarters of the weight lost. (Source 8)
• The regain decelerates rather than overshooting: the authors describe a predictable, decelerating pattern that plateaus below pre-treatment weight, so some benefit persists but is much reduced. (Source 8)

What goes wrong

Nearly half of participants on dulaglutide reported a gastrointestinal adverse event in REWIND, compared with about a third on placebo. (Source 4)

• Randomized trial, High certainty.
• Size: 9,901 participants.
• Who: adults with type 2 diabetes at cardiovascular risk.
• How long: median 5.4 years.
• Result: 2,347 (47.4%) versus 1,687 (34.1%), p<0.0001; an absolute difference of about 13 percentage points.
• Funding: industry-funded (Eli Lilly and Company)

2347 (47·4%) participants assigned to dulaglutide reported a gastrointestinal adverse event during follow-up compared with 1687 (34·1%) participants assigned to placebo (p<0·0001)

Nausea and vomiting rose with dose in AWARD-11. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 1,842 patients.
• Who: adults with type 2 diabetes on metformin.
• How long: 36 weeks.
• Result: nausea 13.4% (1.5 mg), 15.6% (3 mg), 16.4% (4.5 mg); vomiting 5.6%, 8.3%, 9.3%.
• Funding: industry-funded (Eli Lilly and Company); no placebo arm, so these are not drug-versus-placebo rates.

Common adverse events through 36 weeks included nausea (1.5 mg, 13.4%; 3 mg, 15.6%; 4.5 mg, 16.4%) and vomiting (1.5 mg, 5.6%; 3 mg, 8.3%; 4.5 mg, 9.3%).

A French nested case-control study found GLP-1 receptor agonist use for one to three years associated with increased thyroid cancer, including medullary thyroid cancer. (Source 9)

• Case-control study, Low certainty.
• Size: 2,562 thyroid cancer cases matched to 45,184 controls.
• Who: people with type 2 diabetes on second-line antidiabetes drugs in the French national health insurance database, 2006-2018.
• How long: exposure measured over the six years before a six-month lag period.
• Result: all thyroid cancer adjusted HR 1.58 (95% CI 1.27-1.95); medullary thyroid cancer adjusted HR 1.78 (95% CI 1.04-3.05)
• Funding: not stated in the abstract read.

Use of GLP-1 RA for 1–3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04–3.05).

Most of the weight lost on a GLP-1 receptor agonist returns after stopping, with the regain decelerating rather than reaching baseline. (Source 8)

• Meta-analysis, Low certainty.
• Size: 48 studies reviewed; 6 RCTs with 3,236 participants in the meta-regression.
• Who: adults who stopped a GLP-1 receptor agonist.
• How long: up to and beyond 52 weeks after cessation.
• Result: 60% of lost weight regained at one year; extrapolated plateau at 75.3% (95% CI 68.9-81.6) of weight lost; regain half-life 23.0 weeks (95% CI 17.3-34.3)
• Funding: not stated in the summary read; the authors judged most included studies at moderate risk of bias.

At 1 year post-cessation, 60% of the weight lost during treatment was regained. Beyond 52 weeks, weight trajectories were extrapolated, with weight regain estimated to plateau at 75.3% (95% CI 68.9–81.6) of the weight lost on treatment.

In rats, dulaglutide caused a dose-related and duration-related increase in thyroid C-cell tumours over lifetime exposure; the human relevance is undetermined. (Source 2)

• Animal study, Certainty not rated.
• Size: not stated in the label text.
• Who: male and female rats, lifetime exposure.
• How long: lifetime.
• Result: dose-related and treatment-duration-dependent increase in thyroid C-cell adenomas and carcinomas.
• Funding: manufacturer's nonclinical programme, as recorded on the FDA label revised 03/2026.

In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.

What the evidence supports

Dulaglutide reduced the composite of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, with an absolute difference of about 1.4 percentage points over a median 5.4 years. (Source 4)

• Randomized trial, High certainty.
• Size: 9,901 participants (4,949 dulaglutide, 4,952 placebo) at 371 sites in 24 countries.
• Who: adults aged at least 50 with type 2 diabetes and either previous cardiovascular disease or cardiovascular risk factors; median HbA1c 7.2%.
• How long: median follow-up 5.4 years.
• Result: 594 (12.0%) versus 663 (13.4%); 2.4 versus 2.7 events per 100 person-years; HR 0.88 (95% CI 0.79-0.99), p=0.026.
• Funding: industry-funded (Eli Lilly and Company)

the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ratio [HR] 0·88, 95% CI 0·79–0·99; p=0·026)

What the evidence does not support

Dulaglutide did not reduce all-cause mortality in REWIND. (Source 4)

• Randomized trial, High certainty.
• Size: 9,901 participants.
• Who: as above.
• How long: median 5.4 years.
• Result: 536 (10.8%) versus 592 (12.0%); HR 0.90 (95% CI 0.80-1.01), p=0.067.
• Funding: industry-funded (Eli Lilly and Company)

All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80–1·01; p=0·067)

A larger Scandinavian cohort study using an active-comparator design found no increased thyroid cancer risk with GLP-1 receptor agonists. (Source 10)

• Cohort study, Moderate certainty.
• Size: 145,410 GLP-1 receptor agonist users versus 291,667 DPP-4 inhibitor users.
• Who: patients in Denmark, Norway and Sweden, 2007-2021.
• How long: mean follow-up 3.9 years in the GLP-1 group.
• Result: HR 0.93 (95% CI 0.66-1.31); rate difference -0.13 (95% CI -0.61 to 0.36) events per 10,000 person-years; medullary thyroid cancer HR 1.19 (0.37-3.86)
• Funding: not stated in the abstract read.

GLP1 receptor agonist use was not associated with increased risk of thyroid cancer (hazard ratio 0.93, 95% confidence interval 0.66 to 1.31; rate difference −0.13, 95% confidence interval −0.61 to 0.36 events per 10 000 person years).

Where the evidence is mixed

Higher doses of dulaglutide gave dose-related additional HbA1c reduction, but the 3.0 mg dose was not superior to 1.5 mg on the more conservative treatment-regimen estimand. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 1,842 randomly assigned patients.
• Who: adults with type 2 diabetes inadequately controlled on metformin.
• How long: 36 weeks (primary), 52 weeks total.
• Result: 4.5 mg vs 1.5 mg: -1.77% vs -1.54%, ETD -0.24%, P<0.001 (treatment-regimen estimand); 3.0 mg vs 1.5 mg: ETD -0.10%, P=0.096 (treatment-regimen estimand) but ETD -0.17%, P=0.003 (efficacy estimand)
• Funding: industry-funded (Eli Lilly and Company)

Dulaglutide 3.0 mg was superior to 1.5 mg for reducing HbA1c, using the efficacy estimand (ETD −0.17% [−1.9 mmol/mol]; P = 0.003) but not the treatment-regimen estimand (ETD −0.10% [−1.1 mmol/mol]; P = 0.096).

Where the research disagrees

Whether GLP-1 receptor agonists raise the risk of thyroid cancer in people, as they do in rats

• Bezin and colleagues, Diabetes Care 2023 (French national insurance database), nested case-control study, 2,562 cases and 45,184 controls: Use of GLP-1 RA for 1–3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27–1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04–3.05). (Source 9)
• Pasternak and colleagues, BMJ 2024 (Denmark, Norway and Sweden), active-comparator new-user cohort study, 145,410 versus 291,667 patients: GLP1 receptor agonist use was not associated with increased risk of thyroid cancer (hazard ratio 0.93, 95% confidence interval 0.66 to 1.31; rate difference −0.13, 95% confidence interval −0.61 to 0.36 events per 10 000 person years). (Source 10)

How much

• Reference intake: There is no reference intake; dosing is set by the prescriber. The US label, revised 03/2026, records the starting dose as a regulatory position. (Source 11)
• Upper limit: The US label sets the maximum recommended dose as a regulatory position, revised 03/2026. (Source 12)
• Studied: 1.5 mg once weekly by subcutaneous injection versus placebo in REWIND (Source 13)
• Studied: 1.5 mg, 3.0 mg and 4.5 mg once weekly compared head to head in AWARD-11 (Source 3)

A common belief, and what the research shows

The belief: Dulaglutide cuts your risk of dying and the weight loss is permanent.

What the research shows: REWIND, the cardiovascular outcome trial, did reduce heart attacks, strokes and cardiovascular death, but the absolute difference was 12.0% versus 13.4% over a median 5.4 years, and "All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80–1·01; p=0·067)". On weight, a meta-regression of GLP-1 receptor agonist cessation found that "At 1 year post-cessation, 60% of the weight lost during treatment was regained." The benefit is real, modest in absolute terms, and largely conditional on continuing to take it.

Questions and answers

What is it?

Dulaglutide is a once-weekly injection that mimics a natural gut hormone called GLP-1. It is a large protein molecule, almost identical to the human hormone, engineered to last about a week in the blood. (Source 1)

What does it do in the body?

It makes the pancreas release insulin when blood glucose is high, reduces glucagon (which would otherwise push glucose up), and slows the stomach emptying. Together these lower blood sugar after meals and reduce appetite. (Source 1)

Is it good or bad for you?

Both, in measurable amounts. Over five years it prevented roughly one major cardiovascular event for every 70 or so people treated, and it lowers HbA1c and weight. Against that, gastrointestinal side effects are common: in REWIND 47.4% on the drug reported one, versus 34.1% on placebo. (Source 4)

How do you get more of it?

It is a prescription injection, not a nutrient, so there is no dietary or behavioural way to get more of it. The amount is set by the prescriber and escalated slowly to limit nausea; the label records the starting dose as a position. (Source 11)

If it is harmful, what reduces it?

Nothing removes it faster; it clears over weeks after the last injection. What the literature documents is what happens once it is gone: the metabolic effect unwinds, with about 60% of lost weight regained within a year. (Source 8)

Why might someone be low in it or missing it?

The question does not apply in the way it would for a nutrient: no one is naturally low in dulaglutide. It is present only in people prescribed it, and the label restricts that to type 2 diabetes for glycaemic control or cardiovascular risk reduction. (Source 5)

Which whole foods contain it or feed it?

No food contains dulaglutide or feeds it. The food-related point that matters is the reverse: because it slows the stomach emptying, things swallowed around the same time can be absorbed more slowly, most noticeably after the first dose. (Source 6)

What happens if you do not have it?

For someone with type 2 diabetes at cardiovascular risk, not taking it meant a 13.4% rate of heart attack, stroke or cardiovascular death over a median 5.4 years in REWIND, against 12.0% on the drug. Most people in the placebo group did not have an event. (Source 4)

How can you test for it?

Drug levels are not measured in practice; treatment is judged by HbA1c and weight. For the boxed-warning risk specifically, the label states plainly that the obvious screening tests are of uncertain value, which is an unusually direct admission that no reliable monitoring test exists. (Source 2)

References

1. US Food and Drug Administration. TRULICITY (dulaglutide) injection — 12.1 MECHANISM OF ACTION. 2026. Read the source
2. US Food and Drug Administration. TRULICITY (dulaglutide) injection — BOXED WARNING. 2026. Read the source
3. Diabetes Care. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). 2021. PMID 33397768, DOI 10.2337/dc20-1473. Read the source
4. The Lancet. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial — Findings. 2019. PMID 31189511, DOI 10.1016/S0140-6736(19)31149-3. Read the source
5. US Food and Drug Administration. TRULICITY (dulaglutide) injection — INDICATIONS AND USAGE. 2026. Read the source
6. US Food and Drug Administration. TRULICITY (dulaglutide) injection — 7 DRUG INTERACTIONS (oral medications). 2026. Read the source
7. US Food and Drug Administration. TRULICITY (dulaglutide) injection — 7 DRUG INTERACTIONS (insulin secretagogues). 2026. Read the source
8. eClinicalMedicine (The Lancet Discovery Science) 2026;93:103796. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2026. PMID 41938838, DOI 10.1016/j.eclinm.2026.103796. Read the source
9. Diabetes Care. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. 2023. PMID 36356111, DOI 10.2337/dc22-1148. Read the source
10. BMJ. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. 2024. PMID 38683947, DOI 10.1136/bmj-2023-078225. Read the source
11. US Food and Drug Administration. TRULICITY (dulaglutide) injection — 2.1 RECOMMENDED DOSAGE. 2026. Read the source
12. US Food and Drug Administration. TRULICITY (dulaglutide) injection — 2.1 RECOMMENDED DOSAGE (maximum). 2026. Read the source
13. The Lancet. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) — Methods. 2019. PMID 31189511, DOI 10.1016/S0140-6736(19)31149-3. Read the source